(Q40455448)

20 September 2017

title

Ex vivo expansion of human cytomegalovirus-specific cytotoxic T cells by recombinant polyepitope: implications for HCMV immunotherapy. (English)

1 reference

20 September 2017

0 references

1 reference

8

1 reference

20 September 2017

Michael Rist

1

1 reference

20 September 2017

Leanne Cooper

2

1 reference

20 September 2017

Rebecca Elkington

3

1 reference

20 September 2017

Susan Walker

4

1 reference

20 September 2017

Chrysa Fazou

5

1 reference

20 September 2017

Judy Tellam

6

1 reference

20 September 2017

Tania Crough

7

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

European Journal of Immunology

20 September 2017

published in

1 reference

20 September 2017

volume

35

1 reference

20 September 2017

issue

3

1 reference

20 September 2017

page(s)

996-1007

1 reference

Promiscuous CTL recognition of viral epitopes on multiple human leukocyte antigens: biological validation of the proposed HLA A24 supertype

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

Human cytomegalovirus and immunopathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Human cytomegalovirus-specific immunity following haemopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European Group for Blood and Marrow Transplantation (EBMT). Infecti

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Management of CMV infections: recommendations from the infectious diseases working party of the EBMT.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

The cellular immunotherapy of viral infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig–coated artificial antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Characterization of antigen-specific repertoire diversity following in vitro restimulation by a recombinant adenovirus expressing human cytomegalovirus pp65.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Adenovirally transduced dendritic cells induce bispecific cytotoxic T lymphocyte responses against adenovirus and cytomegalovirus pp65 or against adenovirus and Epstein-Barr virus EBNA3C protein: a novel approach for immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Determinants of viral clearance and persistence during acute hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Broad Specificity of Virus-Specific CD4+ T-Helper-Cell Responses in Resolved Hepatitis C Virus Infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Efficient infection of primitive hematopoietic stem cells by modified adenovirus

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Ramifications of HLA class I polymorphism and population genetics for vaccine development.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Function of CMV-encoded MHC class I homologues.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Development of a preventive vaccine for Ebola virus infection in primates

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Supraoptimal peptide-major histocompatibility complex causes a decrease in bc1-2 levels and allows tumor necrosis factor alpha receptor II-mediated apoptosis of cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

The specificity of recognition of a cytotoxic T lymphocyte epitope

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Cytotoxic T cells specific for cytomegalovirus: a potential therapy for immunocompromised patients

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

A complex between the MHC class I homologue encoded by human cytomegalovirus and beta 2 microglobulin

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Presentation of endogenous viral peptide epitopes by anti-CD40 stimulated human B cells following recombinant vaccinia infection.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Three T-cell epitopes within the C-terminal 265 amino acids of the matrix protein pp65 of human cytomegalovirus recognized by human lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425746

7 January 2021

Identifiers

DOI

10.1002/EJI.200425746

1 reference

20 September 2017

1 reference